排名前五的靶点	数量

IFNAR(干扰素α/β受体复合体)	5
TNF-α(肿瘤坏死因子α)	2
HER2(受体蛋白酪氨酸激酶 erbB-2)	2
VEGF x VEGF-A	1
CD40(肿瘤坏死因子受体超家族成员5)	1

关联

项与 Danaher Corp. 相关的药物

Prolgolimab

靶点

PD-1

作用机制

PD-1抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

俄罗斯

首次获批日期2020-04-01

Empegfilgrastim

靶点

CSF-3R

作用机制

CSF-3R激动剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

印度 [+2]

首次获批日期2016-06-01

Cepeginterferon alfa-2b

靶点

IFNAR

作用机制

IFNAR激动剂 [+2]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

俄罗斯

首次获批日期2013-12-01

项与 Danaher Corp. 相关的临床试验

NCT03767231

/ Not yet recruitingN/AIIT

Emergency Department Patient's Perceptions and Acceptability Toward a Novel Point-of-Care Hepatitis C Virus Viral Load Testing

Hepatitis C virus (HCV) infection has become the leading fatal infectious disease in the United States. Approximately 75% of individuals who have been infected with HCV are chronically infected with the virus. Untreated chronic infection will lead to severe sequelae such as cirrhosis and hepatocellular carcinoma. Even though the availability of rapid HCV antibody (HCV Ab) screening assay and highly effective antiviral treatment, most people infected with HCV are not aware of the infection status. This gap mainly comes from the current gold standard confirmatory testing for chronic HCV infection, the Polymerase Chain Reaction (PCR)-based HCV RNA viral load assay which requires an experienced trained laboratory technician to perform relatively complicated PCR assay with a turn-around-time of 1 to 2 days (from provider's order to the test resulting). The investigators' rapid HCV Screening and Linkage to Care program has demonstrated that many patients in the investigators' emergency department (ED) are unaware of patient's chronic HCV infection status due to the barriers to receive the gold standard viral load testing.
Recently, a novel Xpert HCV Viral Load (VL) Finger-stick (FS) [Xpert HCV VL FS] point-of-care (POC) test (Cepheid) has been developed. In an observational cohort in Australia, HCV RNA was detected in 40% of participants (85 of 210) enrolled at 3 drug treatment clinics and 1 homelessness service. Sensitivity of the Xpert HCV VL FS assay for HCV RNA quantification in samples collected by finger-stick was 100.0% (95% Confidence Interval (CI), 93.9%-100.0%) and specificity was 100.0% (95% CI, 96.6%-100.0%). The Xpert HCV VL FS test can accurately detect active infection from a finger-stick sample in 1 hour allowing single-visit HCV diagnosis.
In this protocol, the investigators seek to determine the needs and acceptability of a novel POC HCV viral load testing assay among ED HCV Ab positive patients. For this project, the investigators will identify and enroll ED patients with HCV Ab positive but without HCV viral information. The investigators will conduct a randomized study to assign eligible and consented patients to either to POC Testing Group or Standard of Care (SOC) Group. All participants will take a short survey regarding HCV care and treatment. As part of the investigators' ED HCV Screening and Linkage to Care Program, all participants will receive the standard-of-care clinical laboratory-based HCV RNA viral load testing via whole blood (i.e. patient will receive blood drawn). This standard-of-care HCV viral load testing result will be provided to participant when it is available (usually 1-2 days later). Participants in the POC Testing Group will receive the novel POC HCV RNA viral load testing and the result of the novel test will be disclosed to the patients approximately within 2 hours of the testing. Linkage to care information after the ED visit will be compared between two groups. Finally, accuracy of this POC HCV RNA viral load testing in the acute care setting will be determined as compared to the standard-of-care clinical laboratory-based HCV RNA viral load testing. The investigators will also ask all of participants to grant permission to use the remnant blood specimens for an evaluation of future in-house HCV RNA viral load assay.

开始日期2025-11-01

申办/合作机构

The Johns Hopkins University

[+1]

NCT06669286

/ Not yet recruitingN/A

Retrospective Single Cohort Mono-center Study on Success and Safety of Navigated Implant Placement in Proximity of the Alveolar Nerve

Subjects with severely atrophic mandibles were treated with implants and implant-based restorations. Subjects will be required to consent to study participation and data processing according to General Data Protection Regulation (GDPR). Implant positions were planned digitally in a dental software DTX Studio, and implants placed with navigated surgery (Nobel Biocare X-Guide). Implants eligible for this study must be placed 2 mm or less from the alveolar nerve. Implants placed are NobelParallel TiUnite and NobelActive TiUnite. All subjects were followed up for 1 year after surgery to monitor success and adverse events related to the alveolar nerve. Data analysis will include demographics, medical history, Cone-beam Computed Tomography (CBCT) scans/peri-apical x-ray data, soft tissue parameters, and adverse events.

开始日期2024-12-31

申办/合作机构

CLINICA ODONTOIATRICA VILLA S.R.L.

[+1]

NCT06294574

/ Not yet recruitingN/AIIT

Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction

The purpose of the study is to test how successful the retrieval rate of the new HydroMARK Plus Breast Biopsy Site Marker in comparison to HydroMARK.

开始日期2024-12-01

申办/合作机构

The University of Alabama at Birmingham

[+1]

100 项与 Danaher Corp. 相关的临床结果

登录后查看更多信息

0 项与 Danaher Corp. 相关的专利（医药）

登录后查看更多信息

3,533

项与 Danaher Corp. 相关的文献（医药）

2025-03-01·Laboratory Investigation

NKX3.1 Helps Distinguish Hyalinizing Clear Cell Carcinoma From Other Clear Cell Salivary Gland Neoplasms

Article

作者: Nishino, Shogo ; Fushimi, Chihiro ; Mori, Akiko ; Yatabe, Yasushi ; Sakyo, Airi ; Honma, Yoshitaka ; Takahashi, Hideaki ; Sakai, Toshihiko ; Kobayashi, Kenya ; Kato, Hiroko ; Yoshimoto, Seiichi ; Yokoyama, Kazuki ; Mori, Taisuke ; Sakai, Azusa ; Ryo, Eijitsu ; Hatano, Toshiyuki ; Matsumoto, Fumihiko ; Eguchi, Kohtaro ; Yoshida, Akihiko ; Omura, Go

Hyalinized clear cell carcinoma (HCCC) is a rare tumor of the minor salivary gland, characterized by pale cytoplasm and EWSR1::ATF1 fusion. Recently, new fusions, such as EWSR1::LARP4 and SMARCA2::CREM, have also been identified. Histologically, HCCC closely resembles other salivary gland tumors like mucoepidermoid carcinoma and myoepithelial carcinoma, and there are no specific immunohistological markers for its identification. In this study, we investigated potential markers for HCCC based on the characteristics of minor salivary gland acini, from which these tumors may originate. SOX10 is a known marker for serous gland clusters and NKX3.1 for mucus gland clusters. Fluorescence intensity analysis of double staining, objectively evaluated by artificial intelligence, revealed variations in the positive intensity of cells single positive for NKX3.1 and SOX10, as well as cells positive for both markers, which are commonly observed in normal minor salivary glands. We evaluated NKX3.1 expression by immunohistochemistry in 12 HCCC cases (including 9 EWSR1::ATF1, 1 EWSR1::LARP4, and 1 SMARCA2::CREM), 12 myoepithelial carcinoma cases, and tissue microarray containing 88 cases of multiple salivary gland tumors using immunohistochemistry. NKX3.1 was expressed in all 12 HCCC cases (100%), with NKX3.1-positive cells ≧90% in 3 cases, ≧60% 1 case, ≧30% 4 cases, and <30% 4 cases, respectively. SOX10 was negative in 10 cases and weakly positive in 2 cases. This finding mimics the pattern of expression in minor salivary glands and may explain the occurrence of weak NKX3.1 staining and SOX10-positive cases in HCCC. Additionally, in the tissue microarray analysis, NKX3.1 staining was observed in only 1 HCCC case. These findings indicate that NKX3.1 is a useful marker for distinguishing HCCC from other clear cell salivary gland neoplasms. This study suggests that NKX3.1, along with SOX10 and CK7, can be utilized to improve the accuracy of HCCC diagnosis.

2024-12-31·Autoimmunity

A whole blood-based functional assay to characterize immunoglobulin A effector functions

Article

作者: van Schie, Karin A. ; Toes, René E. M. ; Cartagena García, Celia ; Bacon, Alice ; Busnel, Jean-Marc

Most investigations on the immune cell-activating potency of IgA used purified total IgA and/or specific isolated cell populations. As IgA2 has been reported to be more pro-inflammatory than IgA1, we aimed to employ a fast and convenient whole blood-based assay to individually probe the capacity of the two IgA subclasses to activate immune cells in close physiological conditions. To this end, whole blood from healthy donors (n = 10) was stimulated with immobilized IgA1, IgA2m1 or IgA2m2 (the two main allotypic variants of IgA2). Activation of major leukocyte subsets was measured using a 10-color flow cytometry panel providing access to the expression of 5 activation markers on 6 different immune cell subsets. While capturing some heterogeneity of responses among donors, IgA2m1 and IgA2m2 systematically showed a stronger activation profile compared to IgA1 in a variety of dimensions. For example, both IgA2 allotypes led to stronger modulations of CD54, CD11b, CD62L, CD66b or CD69, on both or either monocytes or neutrophils, indicating a more pronounced pro-inflammatory effect for this subclass than IgA1. By taking into account donor-specific soluble and cellular components this whole blood-based functional approach provides new perspectives to further investigate IgA effector functions in mechanistic studies and/or translational research.

2024-12-23·Open Forum Infectious Diseases

A Rapid Host Response Blood Test for Bacterial/Viral Infection Discrimination Using a Portable Molecular Diagnostic Platform

Article

作者: Scavetta, Joseph ; Iglesias-Ussel, Maria D ; Perelman, Max ; McClain, Micah T ; Ko, Emily R ; Mitsis, Paul G ; van Westrienen, Jesse ; Carittini, Amanda ; Ginsburg, Geoffrey S ; Anderson, Jack ; O’Grady, Nicholas ; Tsalik, Ephraim L ; Tillekeratne, L Gayani ; Camilleri, Clare ; Woods, Christopher W ; Burke, Thomas W ; Naderi, Sepideh ; Henao, Ricardo ; Myers, Rachel A

AbstractBackgroundDifficulty discriminating bacterial versus viral etiologies of infection drives unwarranted antibacterial prescriptions and, therefore, antibacterial resistance.MethodsUtilizing a rapid portable test that measures peripheral blood host gene expression to discriminate bacterial and viral etiologies of infection (the HR-B/V assay on Biomeme's polymerase chain reaction–based Franklin platform), we tested 3 cohorts of subjects with suspected infection: the HR-B/V training cohort, the HR-B/V technical correlation cohort, and a coronavirus disease 2019 cohort.ResultsThe Biomeme HR-B/V test showed very good performance at discriminating bacterial and viral infections, with a bacterial model accuracy of 84.5% (95% confidence interval [CI], 80.8%–87.5%), positive percent agreement (PPA) of 88.5% (95% CI, 81.3%–93.2%), negative percent agreement (NPA) of 83.1% (95% CI, 78.7%–86.7%), positive predictive value of 64.1% (95% CI, 56.3%–71.2%), and negative predictive value of 95.5% (95% CI, 92.4%–97.3%). The test showed excellent agreement with a previously developed BioFire HR-B/V test, with 100% (95% CI, 85.7%–100.0%) PPA and 94.9% (95% CI, 86.1%–98.3%) NPA for bacterial infection, and 100% (95% CI, 93.9%–100.0%) PPA and 100% (95% CI, 85.7%–100.0%) NPA for viral infection. Among subjects with acute severe acute respiratory syndrome coronavirus 2 infection of ≤7 days, accuracy was 93.3% (95% CI, 78.7%–98.2%) for 30 outpatients and 75.9% (95% CI, 57.9%–87.8%) for 29 inpatients.ConclusionsThe Biomeme HR-B/V test is a rapid, portable test with high performance at identifying patients unlikely to have bacterial infection, offering a promising antibiotic stewardship strategy that could be deployed as a portable, laboratory-based test.

1,627

项与 Danaher Corp. 相关的新闻（医药）

2025-01-20

·美通社

Danaher Beacon--丹纳赫集团与复旦大学附属华山医院合作开发阿尔茨海默病诊断新技术

此次Danaher Beacon项目致力于开发更早期、更精确的阿尔茨海默病诊断方法该项目将使用贝克曼库尔特诊断的高灵敏度免疫分析平台和创新检测技术该项目将探索血液生物标志物组合与阿尔茨海默病和其他类型的神经退行性疾病临床结果之间的潜在关联上海 2025年1月20日 /美通社/ -- 全球科学与技术的创新者丹纳赫宣布其旗下运营公司贝克曼库尔特实验系统（苏州）有限公司与复旦大学附属华山医院开展合作，共同开发针对阿尔茨海默病（AD）早期诊断和鉴别诊断的创新解决方案，以更好满足对于阿尔茨海默病更早期、更精准的诊断。这也是丹纳赫携手中国科学家开展的首个Danaher Beacon科研合作项目。阿尔茨海默病是一种常见的导致认知障碍的神经退行性疾病。根据The Lancet Public Health所发表的文献，中国60岁以上人群AD患者总数目前约为983万 [1] 。早期患者临床症状轻微且缺乏特异性，易被忽视，给早期诊断带来困难。随着新型的单克隆抗体药物相继获批上市，AD疾病修饰疗法初见曙光，然而这些疗法的临床应用需要依赖AD的精准诊断。血液生物标志物具有采集方便、适合大规模检查和长期监测等优势，在AD临床实践中发挥着越来越关键的作用。丹纳赫全球副总裁、中国区集团总裁彭阳表示："医疗机构和科研院所是科技突破的策源地。希望通过此次合作携手中国领先医疗机构和临床专家，共同加速神经退行性疾病的科学研究和创新转化。以此为开端，未来我们期望落地更多Danaher Beacon项目，发挥丹纳赫在技术和产业端的优势，支持创新成果转化。" 丹纳赫中国医学诊断平台总裁陈小穗表示："在神经退行性疾病血液标志物检测有机会进入临床常规检测项目的预期下，贝克曼以Danaher Beacon研究项目为起点，致力于以高质量、标准化、更及时、更可及的检测方案来满足临床医生早筛早诊需求，为推进下一代诊断和治疗方案在中国落地奠定基础。" 丹纳赫中国首席科学官方焯博士进一步阐述："华山医院神经认知领域顶尖的科研团队与贝克曼库尔特领先的技术相结合，探索血液标志物组合与临床诊疗结果之间的关联，推进血液标志物在临床实践中的转化应用，为阿尔茨海默病的早期识别与精准诊断带来新的突破。" 华山医院神经内科副主任郁金泰："血液检测具有微创且操作便捷的优势，但在血液中寻找疾病的生物标志物依然面临很大挑战。我们非常高兴能够与丹纳赫这样全球领先的科技领导者合作。期待通过我们双方的一致努力，为阿尔茨海默病的早期识别和精准诊断带来新突破，通过更高灵敏度、更易于普及的诊断，让真正潜在患者得到临床的最大获益。" 这是第一个落地中国的Danaher Beacon项目。华山医院神经内科郁金泰教授与丹纳赫旗下运营公司贝克曼库尔特，利用高灵敏度诊断技术平台，共同探索新型血液生物标志物组合与阿尔茨海默病临床结果之间的潜在关联，推进血液生物标志物在临床上的转化应用，以提高早期诊断和鉴别诊断的准确度，进而优化治疗方案，延缓疾病进展，改善患者生活质量。与此同时，此次合作开发技术还将有望用于诊断其他类型的神经退行性疾病和神经免疫性疾病。 Danaher Beacon项目是丹纳赫联合顶级学术机构、科研院在全球范围内发起的一项前沿科学研究计划，旨在开展前沿性的科学研究，开发改善人类健康的创新技术和应用。该项目专注的领域包括基因组药物、精准诊断、下一代生物制品制造、人类系统和数据科学等。关于丹纳赫丹纳赫是生命科学与医学诊断领域的创新者，致力于加速科技进步，改善人类健康。我们与客户密切协作，解决全球患者面临的诸多重大健康挑战。丹纳赫的先进科学与技术，以及久经验证的创新力，不仅能够帮助实现更快速、更准确的医学诊断，更能有效地缩短时间降低成本，从而可持续地发现、开发和交付改变生命的疗法。秉承科学卓越、追求创新和持续改善的理念，丹纳赫全球约63,000名员工帮助提高当今数十亿人的生活质量，同时为建设一个更健康、更可持续的未来奠定基础。了解更多信息，敬请访问 www.danaher.com.cn。参考文献： 1. Jia, Longfei et al. "Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study." The Lancet. Public health Vol. 5,12 (2020)

临床研究

2025-01-19

·Cytiva学堂

Cellular Origins与Cytiva携手推进细胞和基因疗法的自动化机器人生产

全球生命科学领域的先行者Cytiva（思拓凡）与致力于推进可放大、高成本效益的细胞与基因疗法（CGT）生产的TTP旗下公司Cellular Origins达成合作，旨在变革细胞疗法的生产方式。通过将Cytiva的自动化Sefia平台与Cellular Origin的自动化机器人平台Constellation相结合，CGT生产商将能够将生产规模放大到工业水平，而无需改变发现阶段或临床试验期间使用的工艺。这两个系统将无缝对接，提供完整的数字互联，包括质量控制系统、完全远程进行的数字控制和分析。可免去人工干预各个CGT生产步骤的必要，有助于推动自动化和生产效率新标准的落地。 Cellular Origins首席执行官Edwin Stone表示： “ 细胞和基因疗法的生产必须从个性化和小批量药物生产拓展到工业化生产，只有这样才能让此类疗法造福更多潜在患者。Cellular Origins正在努力实现这一目标。通过与生命科学领域的先行者Cytiva合作，我们正在建立一个统一的自动化平台，以满足该行业的大规模工业化需求。 ” Cytiva基因药物运营公司全球总裁Emmanuel Abate表示： “ 无数患者曾受益于Cytiva的细胞处理系统，我们仍然对CAR-T的治疗潜力满怀憧憬。我们坚信，相关生产流程的自动化能够让此类疗法惠及更多病患，拯救更多生命。Cellular Origins设计的开放性与Cytiva的Sefia平台无缝整合，可使众多疗法研发方获益。我们很高兴看到我们的合作有望打开未来医学的新局面。 ” 目前，47%的接诊患者可以接受CAR-T疗法1。CAR-T疗法的个性化特点及其临床疗效改变了患者的命运。然而，目前的生产实践严重依赖人力，增加了流程的复杂性和可变性。此外，有限的生产能力、批次失败的重大风险以及监管部门对更广泛适应症的审批日益严格，都将使药品开发商在满足患者日益增长的需求方面面临更大挑战。 Cytiva和Cellular Origins认识到，模块化的机器人解决方案将帮助生产商将CGT疗法的数量从每年数千个扩展到数十万个。合并后的解决方案将把两个系统无缝集成到客户现有的工作流程中，使客户能够全天候生产获得商业批准的后期CGT产品，而无需更改系统或重新设计已获批准的工艺流程。这种合作是对优化的持续投资，其益处包括提高生产空间效率、降低劳动力要求和减少CGT的总体成本，从而消除或减少普及CGT疗法的一些主要障碍。目前双方正在有条不紊地推进这项壮举，首批系统将于2025年初进行工艺和生物测试。预计到2025年底，GMP 系统将可用于临床。 Cytiva和Cellular Origins将于1月20至24日在ATW 2025的435号展位上展示其Sefia和Constellation平台。 1Strengthening Pathways for Cell and Gene Therapies: IQVIA Institute, March 2024 Cytiva和Sefia是Global Life Sciences Solutions USA LLC或以Cytiva名义开展业务的关联公司的商标。关于Cellular Origins Cellular Origins是TTP旗下的子公司，致力于开发用于细胞和基因疗法（CGT）的工业化和数字化生产的自动化机器人生产平台。Cellular Origins与业界领先的技术和生产创新企业合作，利用其先进的移动机器人生态系统Constellation，帮助细胞疗法开发商和CDMO 实现现有流程和技术的完全自动化。这使得Cellular Origins能够提供符合GMP标准的全自动解决方案，可扩展细胞疗法的生产规模、提供无与伦比的生产效率、精确性和可放大性。Cellular Origins公司总部位于英国剑桥。关于Cytiva 我们的使命是推动未见技术，加速非凡疗法。我们在全球40余个国家和地区拥有约15,000名员工，致力于利用我们的专业知识和人才，为客户提供更好的灵活性、产能和效率。我们广泛而深入的工具和技术组合、全球规模以及一流的服务，可为研究人员、新兴生物技术公司、大型生物制药公司和合同生产商等客户提供从药物发现到交付的全流程支持。

细胞疗法基因疗法免疫疗法临床研究

2025-01-17

·Business Wire

Cutting-Edge Digital Biomanufacturing Solutions Drive $39.6 Billion Surge in Global Bioprocess Optimization Market - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Bioprocess Optimization and Digital Bio-manufacturing: Global Markets" report has been added to ResearchAndMarkets.com's offering. The Global Bioprocess Optimization and Digital Bio-manufacturing Market was valued at USD 24.3 Billion in 2024, and is expected to reach USD 39.6 Billion by 2029, rising at a CAGR of 10.20%. The report provides a comprehensive analysis of the bioprocess optimization and digital biomanufacturing market in a global context, including market forecasts and sales through the year 2029. Segmentation based on technology type includes manufacturing technologies (chromatography-based separation and purification, filtration, bioreactors, centrifugation), analytical and process control technologies (spectrophotometry, automation and industrial process control technologies, analytical chromatography, sensors and probes), and software (Industrial control and automation software, bioprocess optimization and data analytics software). Segmentation based on application includes biomanufacturing process automation and control, flexible manufacturing, bioprocess optimization and process analytics, and others. By molecule type the market is segmented into monoclonal antibodies, vaccines, therapeutic proteins and peptides, and cell and gene therapies. The regional markets covered are North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The report discusses the critical issues impacting the adoption of digital biomanufacturing in pharmaceuticals, as well as emerging trends in digital biomanufacturing technologies. It also features new developments and new product launches in the global market. The report provides comprehensive profiles of market players in the industry. The report also covers mergers and acquisitions and any other collaborations or partnerships that occurred during the evaluation period of this report and which are expected to shape the industry. Report Scope 69 data tables and 61 additional tables Analyses of trends in the global market for bioprocess optimization and digital bio-manufacturing, with market revenue data for 2021-2023, estimates for 2024, forecasts for 2025, and projected CAGRs through 2029 Estimates of the market size and revenue growth prospects of the global market, along with a market share analysis by technology, application, drug molecule type and region Facts and figures pertaining to the market dynamics, technical advances, regulations and the impact of macroeconomic factors Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses Analysis of patents, emerging trends, and new developments Analysis of the industry structure, including companies' market shares, strategic alliances, M&A activity and a venture funding outlook Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies Profiles of the market leaders, including Agilent Technologies Inc., Thermo Fisher Scientific Inc., Danaher Corp., and Sartorius AG. Key Attributes: Report Attribute Details No. of Pages 180 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $24.3 Billion Forecasted Market Value (USD) by 2029 $39.6 Billion Compound Annual Growth Rate 10.2% Regions Covered Global Key Topics Covered: Chapter 1 Introduction Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Technology Background Biologics Manufacturing Process Upstream Processing Cell Harvesting and Clarification Downstream Processing Bioprocess Optimization Industry 4.0 - Digital Biomanufacturing Chapter 3 Market Dynamics Market Drivers Growing Aging Population Increasing Prevalence of Chronic Diseases Unprecedented Rise in Demand for Biopharmaceuticals Growing Number of Product Launches Increasing Number of Contract Manufacturing Organizations (CMOs) Market Restraints Lack of Skilled Labor High Cost of Equipment Unharmonized Smart Manufacturing Standards Market Opportunities Favorable Government Programs Advances in Sensor Technology Process Analytical Technology Initiatives Market Challenges Technical Issues and the Threat of Cyberattacks Regulatory Landscape Good Automation Manufacturing Practices (GAMP) Instrumentation, Systems, and Automation (ISA) Society-88 and 95 Standards Chapter 4 Emerging Technologies and Developments Emerging Trends and Technologies Continuous Bioprocessing Continuous Cell Retention Technologies Continuous Chromatography Single-Use Technologies Chapter 5 Market Segmentation Analysis Market Analysis by Technology Manufacturing Technologies Analytical and Process Control Technologies Software Market Analysis by Application Biomanufacturing Process Automation and Control Flexible Manufacturing Bioprocess Optimization and Process Analytics Other Applications Market Analysis by Molecule Type Monoclonal Antibodies (mAbs) Therapeutic Proteins and Peptides Vaccines Cell and Gene Therapies Market Analysis by Region Chapter 6 Competitive Intelligence Ranking of Leading Players Key Strategies Adopted by Players Collaborations and Partnerships Expansion Acquisitions New Product Launches Chapter 7 Sustainability in the Bioprocess Optimization and Digital Biomanufacturing Market: An ESG Perspective ESG Practices in the Industry Companies' ESG Risk Ratings Company Profiles Agilent Technologies Agilitech Bio-Rad Laboratories Bruker Clean Biologics Danaher Emerson Electric Eppendorf Korber Merck Sartorius Shimadzu Thermo Fisher Scientific Univercells Technologies Waters For more information about this report visit https://www.researchandmarkets.com/r/vlkua2 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 项与 Danaher Corp. 相关的药物交易

登录后查看更多信息

100 项与 Danaher Corp. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年01月30日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

临床3期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

干扰素β-1b生物类似药(Biocad Medical, Inc.) ( IFNAR )	多发性硬化症更多	批准上市
干扰素α-2b/牛磺酸/苯佐卡因 ( IFNAR x Nav1.8 )	乳头状瘤病毒感染更多	批准上市
曲妥珠单抗生物类似药(Biocad Medical, Inc.) ( HER2 )	乳腺癌更多	批准上市
Cepeginterferon alfa-2b ( IFNAR )	丙型肝炎更多	批准上市
干扰素β-1a生物类似药(Biocad Medical, Inc.) ( IFNAR )	多发性硬化症更多	批准上市